Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells

Avi Eisenthal*, Hanoch Kashtan, Micha Rabau, Vankatesh Ramakrishna, Samario Chaitchik, Yehuda Skornick

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


In the present study we evaluate the antitumor efficacy of a glycosylated molecule of interleukin-6 (IL-6), which was cloned and expressed in Chinese hamster ovary cells. When tested with two syngeneic murine tumors, the MC38 adenocarcinoma and the MCA106 fibrosarcoma, recombinant IL-6 (rIL-6) significantly reduced the number of day-3 established MC38 lung metastases, but had no effect on MCA106 lung metastases. A similar effect of rIL-6 was seen on day-3 MC38 liver metastases. The antitumor activity mediated by rIL-6 was achieved at doses of the cytokine ranging from 6 μg to 150 μg/day. There was no correlation between the responsiveness to rIL-6 of these two tumors and their susceptibility, in vitro, to a direct cytostatic effect of the cytokine or the increase in the expression of major histocompatibility complex (MHC) antigens after exposure to rIL-6. However, a correlation was seen between the antitumor response to rIL-6 and the initial number of tumor cells expressing MHC antigens. The possible role of MHC antigens expressed on tumor cells, the generation of MHC-restricted cytotoxic cells and the responsiveness to IL-6 are discussed.

Original languageEnglish
Pages (from-to)101-107
Number of pages7
JournalCancer Immunology, Immunotherapy
Issue number2
StatePublished - Mar 1993


  • ADCC
  • Cytokines
  • Eukaryotic cells
  • Immunotherapy
  • Recombinant interleukin-6


Dive into the research topics of 'Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells'. Together they form a unique fingerprint.

Cite this